Antibody–drug conjugate significantly improves PFS, OS in triple-negative breast cancer
Sacituzumab govitecan-hziy (Trodelvy, IImmunomedics, Inc), significantly extended overall survival (OS) and improved overall response rate (ORR) and clinical benefit rate (CBR), compared to standard single-agent chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC) previously received ≥2 prior therapies for metastatic disease, according to data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
Patients treated with sacituzumab govitecan-hziy in the ASCENT study had a median OS of 12.1 months copmarped with 6.7 months in those treated with chemotherapy. Patients receiving sacituzumab govitecan-hziy also had a statistically significant improvement in ORR (35%) and CBR (45%) versus 5% and 9%, respectively, in patients receiving chemotherapy. In the treatment arm, 4% of patients had complete responses compared with 1% in the control group.
“The randomized Phase 3 study results confirm that sacituzumab govitecan should be considered as a new standard of care in patients with third-line mTNBC,” stated Aditya Bardia, MD, MPH, Director of Precision Medicine at the Center for Breast Cancer, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, in a press release. “We wish to express our gratitude to the patients and their caregivers for their valuable contribution, as well as the dedicated clinical trial investigators and their devoted team members for making the ASCENT trial possible. Ongoing studies are evaluating sacituzumab govitecan in earlier lines of therapy, including the neoadjuvant and adjuvant settings, in combination with other targeted agents, and in patients with hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer, which will help accelerate our efforts to further improve outcomes for patients with breast cancer.”
Bardia A, et al. ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Presented at: ESMO Virtual Congress 2020, LBA17